Get the Daily Brief
Latest Biotech News
Alzheimer’s and Neurodegeneration Research Advances
Multiple studies highlight progress in understanding and treating neurodegenerative diseases. New data suggest that amyloid-clearing Alzheimer’s drugs from Eli Lilly and Eisai have amplified...
Regulatory and Market Sentiment Shifts in Biotech
The biotech and healthcare sectors are navigating volatile regulatory and market environments. FDA leadership changed with Vinay Prasad's departure amid controversies. NeoGenomics faced stock...
FDA Clears Sarepta to Resume Gene Therapy Shipments for Duchenne Muscular Dystrophy – Ambulatory Patients Back on Track
After a week-long pause initiated due to safety concerns following patient fatalities, the U.S. Food and Drug Administration (FDA) has authorized Sarepta Therapeutics to resume shipments of its...
Novo Nordisk Downgrades 2025 Sales Outlook as Obesity Drug Faces Market Challenges – Leadership Transition Unfolds
Danish pharmaceutical leader Novo Nordisk has revised down its full-year 2025 sales growth forecast for its flagship GLP-1 products Wegovy and Ozempic to 8%–14%, from an earlier 13%–21%...
GeneDx Posts 49% Revenue Growth Fueled by Genome and Exome Testing Expansion
Genetic diagnostics company GeneDx reported strong second-quarter 2025 financial results with revenues reaching $102.7 million, up 49% year-over-year. The growth was driven by a substantial 69%...
Merck Initiates $3 Billion Cost-Cutting Effort to Finance New Product Launches – Portfolio Transformation Underway
Merck & Co. unveiled a major multiyear cost optimization initiative aimed at reducing annual expenses by $3 billion by the end of 2027. This strategy will redirect funds from mature assets toward...
GSK and Hengrui Ink $12.5 Billion Deal Targeting COPD and Oncology Pipeline Expansion
GlaxoSmithKline plc (GSK) and China-based Hengrui Pharmaceuticals Co. Ltd. entered into a strategic collaboration valued at up to $12.5 billion to develop and commercialize up to 12 drug...
Apellis Pharmaceuticals’ Empaveli Gains FDA Approval for Rare Kidney Disorders – Expands Market Potential
Apellis Pharmaceuticals and Sobi secured FDA approval for pegcetacoplan (Empaveli) to treat complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis...
NeoGenomics Stock Dips After Revenue Miss and Lowered 2025 Guidance Amid Competitive Challenges
NeoGenomics reported a 10% growth in second-quarter 2025 revenues to $181.3 million, but results fell short of analyst expectations. The company lowered its full-year revenue and earnings...
Virtual Laboratory AI Agents Accelerate Complex Biomedical Research with Interdisciplinary Collaboration
Researchers from Stanford University and Chan Zuckerberg Biohub have developed an innovative AI-driven “Virtual Lab” system that mimics a multidisciplinary scientific team led by a principal...
Celcuity's Breast Cancer Therapy Gedatolisib Delivers Breakthrough Phase III Results – Stock Soars
Minneapolis-based Celcuity announced positive top-line data from its phase III Viktoria-1 study evaluating gedatolisib in combination with standard treatments for HR-positive, HER2-negative,...
Trade Deal Imposes 15% Tariffs on Pharma Imports in US-EU Agreement – Industry Impacts Weighed
The new trade agreement between the United States and the European Union includes a 15% tariff on pharmaceutical imports, marking a significant departure from previous zero-duty policies. Analysts...
FDA Clears Sarepta’s Duchenne Therapy Shipments for Ambulatory Patients
The FDA reversed its earlier hold and has authorized Sarepta Therapeutics to promptly resume shipments of Elevidys, its gene therapy for ambulatory Duchenne muscular dystrophy (DMD) patients. This...
Merck’s $3B Cost-Cutting Drive Signals Strategic Shift Amid Pipeline Challenges
Merck & Co. announced a comprehensive cost-saving initiative aiming to cut $3 billion annually by 2027, alongside a strategic shift focusing investment on newer product launches and pipeline...
Novo Nordisk Faces Sales Downgrade as CEO Changes Amid Obesity Drug Competition
Danish pharmaceutical leader Novo Nordisk announced significant downward revisions to its 2025 sales and operating profit forecasts due to competition from low-cost semaglutide knockoffs impacting...
Celcuity Breast Cancer Drug Shakes Market After Positive Phase III Results
Celcuity reported strong phase III clinical results for gedatolisib in combination therapies targeting hormone receptor-positive, HER2-negative breast cancer lacking PI3KCA mutations. The therapy...
GSK and Hengrui Ink $12.5 Billion Collaboration for Respiratory and Oncology Assets
GSK plc expanded its respiratory and immunology portfolio through a strategic partnership with Hengrui Pharmaceuticals. The deal includes a $500 million upfront payment for an exclusive global...
GeneDx Reports Surge in Genome and Exome Testing Revenues, Boosts 2025 Guidance
Gaithersburg-based genetic diagnostics company GeneDx reported a 49% year-over-year revenue increase in Q2 2025 to $102.7 million, driven largely by whole-exome and whole-genome testing which...
Apellis’ Empaveli Gains FDA Approval for Rare Kidney Diseases
Apellis Pharmaceuticals received FDA approval for an expanded indication of its complement 3 (C3) inhibitor pegcetacoplan, marketed as Empaveli, for two rare kidney disorders: complement 3...
Boehringer and Re-Vana Partner in Eye Health with Potential $1B Deal
Boehringer Ingelheim has expanded its ophthalmology portfolio by entering a collaboration with Re-Vana Therapeutics to develop extended-release ocular therapies. The potential partnership, valued...